NCT02049307
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
See it on ClinicalTrials.gov ↗108 people
96.3%
4 womenmiddle line = equal numbers104 men
- Phase
- PHASE2
- Paid for by
- Hennepin Healthcare Research Institute
- Finished
- 2018-12-14
- Health conditions
- Inflammation, Fibrosis
- Who could join
- Anyone
- Ages
- 50 Years – no maximum
- Average age
- mean 57 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 55.6% · Black / African American 34.3% · Hispanic / Latina 10.2%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy or breastfeeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnancy or breastfeeding”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Cirrhosis or end-stage liver disease”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD), stroke, or diabetes mellitus (DM))”
- No diabetes
Women with diabetes were turned away.
“A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD), stroke, or diabetes mellitus (DM))”
- No cancer
Women with current or past cancer were turned away.
“Invasive cancer in the prior year or receiving cancer treatment (not including carcinoma-in-situ or basal cell cancer of the skin)”
Study titles and rules are shown in their original English.